Journal
CURRENT ATHEROSCLEROSIS REPORTS
Volume 23, Issue 8, Pages -Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11883-021-00936-1
Keywords
Cholesterol; Triglycerides; RNA; Antisense oligonucleotides; Apolipoproteins; ANGPTL3; Lipoprotein(a)
Categories
Funding
- Conselho Nacional de Pesquisa e Desenvolvimento Tecnologico, Brazil, (CNPq) [303734/2018-3]
Ask authors/readers for more resources
Advances in RNA-targeted therapies have shown promising results in treating dyslipidemia, with inhibition of proteins like PCSK9, apoB, apo(a), apoC3, and ANGPTL3. These therapies, including ASO and siRNA molecules, effectively reduce protein synthesis, improve dyslipidemia, and have demonstrated good tolerability in clinical trials.
Purpose of Review To discuss advances on the RNA-targeted therapies to treat dyslipidemia with the aim of reducing atherosclerotic cardiovascular disease (ASCVD). Recent Findings Genetic studies have paved the way for therapies that reduce translation of proteins that play causal roles in dyslipidemia and atherosclerosis like proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein B-100 (apoB), apolipoprotein(a) [apo(a)], apolipoprotein C3 (apoC3), and angiopoietin-like 3 (ANGPTL3). Either antisense oligonucleotide (ASO) therapies and small interfering RNA (siRNA) molecules inhibit protein synthesis and consequently improve dyslipidemia. Most of these molecules contain N-acetylgalactosamine (GalNAc) moieties that have high specificity for hepatocytes and therefore reduce concentration in other tissues. Inclisiran, an siRNA for PCSK9, has shown robust LDL-C reductions, with good tolerability, in severe forms of hypercholesterolemia as well as in high cardiovascular disease patients with injections every 3 to 6 months. Pelacarsen is an ASO against apolipoprotein(a) that reduces Lp(a) up to 80% with good tolerability. Either inclisiran or pelacarsen is being tested to show it can prevent ASCVD. AMG 890, an siRNA compound aimed at reducing apo(a) synthesis, is also under investigation. Volanesorsen is an ASO against apoC3 that reduces triglyceride levels up to 70% and is being tested in severe hypertriglyceridemic patients. Vupanorsen is an ASO against ANGPTL3 that reduced triglyceride levels 36-53% among moderate hypertriglyceridemic individuals. Interestingly, it also reduces ApoC3 and non-HDL cholesterol and apoB; however, it lowers HDL cholesterol. RNA-targeted therapies are being extensively tested for dyslipidemia treatment with promising results.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available